Weigerstorfer Philippe 4

What Happened

• Philippe Weigerstorfer, a director of Sonoma Pharmaceuticals, was granted a 10,000-share derivative award (stock options) on July 9, 2026. The filing lists the shares as a derivative grant with no exercise price or immediate cash value reported (N/A).

Key Details

• Transaction date: 2026-07-09 (award/grant, code A).
• Amount: 10,000 shares (derivative — options); price/exercise value: N/A in the filing.
• Shares owned after transaction: not specified in this Form 4.
• Footnotes: F1 — options vest one-third on 7/9/2027, one-third on 7/9/2028, and one-third on 7/9/2029, or fully vest upon a change of control. F2 — award granted for services performed on the Board of Directors.
• Filing timeliness: Reported for the same date as the transaction (no late filing indicated).

Context

• This was a grant of options/awards for board service, not a purchase or sale of already-issued shares. Because the award vests over time (or on a change of control), it does not represent immediately tradable shares. The filing provides no exercise price or immediate dollar value, so the economic impact depends on future stock performance and any disclosed exercise terms.